Director/PDMR Shareholding
Oxford Biomedica PLC announced that Kathleen Miller, Head of US Human Resources, exercised 3,315 Restricted Stock Units under the Long Term Incentive Plan and subsequently sold 1,167 ordinary shares on the London Stock Exchange on October 6, 2026, at a price of £5.518 per share, generating £6,438.92 from the sale.
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Oxford, UK – 6 October 2026: OXB (LSE: OXB) (the “Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that Kathleen Miller, Head of US Human Resources (and acting Interim Site Head, Bedford) has exercised 3,315 Restricted Stock Units (“RSU”) awards granted under the Long Term Incentive Plan (“LTIP”) and sold 1,167 ordinary shares of 50p each (“Ordinary Shares”) in the Company on 6 October 2026 on the London Stock Exchange at a price of £ 5.518.
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Kathleen Miller | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Head of US Human Resources (and acting Interim Site Head, Bedford) | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 06-October 2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Exercise of RSU Awards | ||||
| e) | Place of the transaction | Outside the trading venue | ||||
| f) | Currency | GBP – British Pound | ||||
| g) | Price(s) and volumes(s) | Price(s) Volume(s) £nil 3,315 | ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,315 £Nil £Nil | ||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Kathleen Miller | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Head of US Human Resources (and acting Interim Site Head, Bedford) | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 06-October 2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Sale of shares | ||||
| e) | Place of the transaction | London Stock Exchange (XLON) | ||||
| f) | Currency | GBP – British Pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 1,167 £5.518 £6,438.92 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.